CL2022000107A1 - Anticuerpos anti-grp78 y método de uso de los mismos - Google Patents

Anticuerpos anti-grp78 y método de uso de los mismos

Info

Publication number
CL2022000107A1
CL2022000107A1 CL2022000107A CL2022000107A CL2022000107A1 CL 2022000107 A1 CL2022000107 A1 CL 2022000107A1 CL 2022000107 A CL2022000107 A CL 2022000107A CL 2022000107 A CL2022000107 A CL 2022000107A CL 2022000107 A1 CL2022000107 A1 CL 2022000107A1
Authority
CL
Chile
Prior art keywords
antigen
grp78
cancer
useful
binding proteins
Prior art date
Application number
CL2022000107A
Other languages
English (en)
Inventor
Dennis Hallahan
Vaishali Kapoor
Abhay Kumar Singh
Original Assignee
Washington University St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University St Louis filed Critical Washington University St Louis
Publication of CL2022000107A1 publication Critical patent/CL2022000107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención está dirigida a anticuerpos aislados que se unen a GRP78. Específicamente, composiciones que comprenden proteínas de unión a antígeno anti-GRP78 útiles para el reconocimiento de células cancerígenas o tumorales. Además, en algunos aspectos, las proteínas de unión a antígeno anti-GRP78 son útiles para la administración de fármacos y terapias específicas para el tumor o el cáncer. En otro aspecto, las proteínas de unión a antígeno divulgadas son útiles para mejorar la radioterapia en un sujeto que tiene o se sospecha que tiene cáncer o un tumor, donde la proteína de unión a antígeno se conjuga con una carga útil, por ejemplo, un agente terapéutico, un agente de formación de imágenes, o una combinación de los mismos
CL2022000107A 2019-07-16 2022-01-14 Anticuerpos anti-grp78 y método de uso de los mismos CL2022000107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962874791P 2019-07-16 2019-07-16

Publications (1)

Publication Number Publication Date
CL2022000107A1 true CL2022000107A1 (es) 2022-10-21

Family

ID=74211341

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000107A CL2022000107A1 (es) 2019-07-16 2022-01-14 Anticuerpos anti-grp78 y método de uso de los mismos

Country Status (15)

Country Link
US (1) US20220259322A1 (es)
EP (1) EP3999547A4 (es)
JP (1) JP2022541765A (es)
KR (1) KR20220034823A (es)
CN (1) CN114585647A (es)
AU (1) AU2020314851A1 (es)
BR (1) BR112022000778A2 (es)
CA (1) CA3147606A1 (es)
CL (1) CL2022000107A1 (es)
CO (1) CO2022001643A2 (es)
IL (1) IL289905A (es)
MX (1) MX2022000671A (es)
PE (1) PE20220646A1 (es)
WO (1) WO2021011798A1 (es)
ZA (1) ZA202201160B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304680B (zh) * 2022-03-11 2024-02-02 四川大学华西医院 基于Pep42构建的双特异性细胞接合器分子的制备及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001245945A1 (en) * 2000-03-23 2001-10-03 Pe Corporation (Ny) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
US20080131451A1 (en) * 2004-03-05 2008-06-05 Giancarlo Tanzi Epitope escape mutations
MX2008000429A (es) * 2005-07-18 2008-03-10 Basf Plant Science Gmbh Aumento del rendimiento en plantas con sobreexpresion de los genes accdp.
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2013019730A1 (en) * 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CN105452292A (zh) * 2013-03-14 2016-03-30 帕卡什·吉尔 使用结合细胞表面grp78的抗体进行癌症治疗
RU2733754C2 (ru) * 2015-05-20 2020-10-06 Те Брод Инститьют Инк. Общие неоантигены

Also Published As

Publication number Publication date
WO2021011798A1 (en) 2021-01-21
PE20220646A1 (es) 2022-04-28
JP2022541765A (ja) 2022-09-27
IL289905A (en) 2022-03-01
BR112022000778A2 (pt) 2022-04-12
CA3147606A1 (en) 2021-01-21
US20220259322A1 (en) 2022-08-18
KR20220034823A (ko) 2022-03-18
ZA202201160B (en) 2022-09-28
AU2020314851A1 (en) 2022-02-10
CO2022001643A2 (es) 2022-05-31
CN114585647A (zh) 2022-06-03
EP3999547A4 (en) 2023-07-12
EP3999547A1 (en) 2022-05-25
MX2022000671A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
ECSP19078502A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
CY1123110T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
CY1123586T1 (el) Υποδορια σκευασματα αντισωματος her2
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
CO2021016552A2 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
BR112018075198A2 (pt) método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CR20230191A (es) NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584)
PE20210375A1 (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
ZA201907225B (en) Treatment of her2 positive cancers
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
ECSP20063690A (es) Anticuerpos
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
BR112018076639A2 (pt) quimioterapias de combinação
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
BR112019011350A2 (pt) terapia de combinação
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap